Eisai, Shire Of U.K. Get Warning Letters About Dacogen Promotion
This article was originally published in PharmAsia News
Executive Summary
Eisai and U.K.-based Shire have received warning letters from U.S. FDA about the way they are promoting their myelodysplastic syndrome drug